我武生物(300357.SZ):獲得黃花蒿花粉變應原舌下滴劑上市後臨牀試驗總結報告
格隆匯7月22日丨我武生物(300357.SZ)公佈,日前,浙江我武生物科技股份有限公司產品“黃花蒿花粉變應原舌下滴劑”(以下簡稱“本品”)完成了“黃花蒿花粉變應原舌下滴劑對成人變應性鼻炎患者的長期療效和安全性評價——多中心、開放性臨牀試驗”,並形成了臨牀試驗總結報告。
本次臨牀試驗的安全性分析結果顯示安全性良好,發生的不良反應嚴重程度主要爲1級和2級。不良反應種類與本品成人III期臨牀安全性數據以及藥品說明書中的不良反應數據高度一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.